Phase I/II Study of SIR-Spheres Plus Sorafenib (Chemo-Radiotherapy) as First Line Treatment in Patients With Non-Resectable Primary Hepatocellular Carcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 27 Jan 2016
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 17 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Jun 2009 Planned number of patients changed from 31 to 35 as reported by ClinicalTrials.gov.